Tazeen Ahmad
BofA Securities, Research Division

Good afternoon, everybody. Welcome back to the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm one of the senior biotech analysts at the bank. It's my pleasure to have our next presenting company here, Incyte. Presenting for Incyte up here on stage with me is Bill Meury, who is, of course, President and CEO. Bill, thanks for making the trip out West to see us.

William Meury
CEO & Director

Thanks, Tazeen. It's good to be here.

Tazeen Ahmad
BofA Securities, Research Division

So it's been quite the year of transformation for Incyte. So I thought maybe we usually start off by asking for an overview of the company, but I thought I would switch it up a little bit with you. And have you tell me what it's been like to be at Incyte since you became the new CEO a while back last year.

William Meury
CEO & Director

Yes. Thank you. It's a good question. It's been about a year. And I can tell you that I did a lot of diligence before coming in. I had an opportunity to speak with the members of the Board for an extensive period of time. And there have been nothing but good surprises so far. One of the reasons I joined is I thought that the core business as well as the pipeline was somewhat underappreciated. I think there's a lot of substrate and potential for meaningful product flow over the next several years. And that's just going to be important in terms of replacing Jakafi and going beyond Jakafi with multiple growth drivers.